Julie Earl

List of Publications by Year
in descending order

48 papers	1,757 citations	471371 17 h-index	315616 38 g-index
51 all docs	51 docs citations	51 times ranked	4034 citing authors

#	Article	IF	Citations
1	Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert Centers. Journal of Clinical Oncology, 2016, 34, 2010-2019.	0.8	280
2	Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy. Nature Genetics, 2013, 45, 1464-1469.	9.4	224
3	Circulating tumor cells (CTC) and KRAS mutant circulating free DNA (cfDNA) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer. BMC Cancer, 2015, 15, 797.	1.1	147
4	Mosaic loss of chromosome Y is associated with common variation near TCL1A. Nature Genetics, 2016, 48, 563-568.	9.4	134
5	Mosaic Uniparental Disomies and Aneuploidies as Large Structural Variants of the Human Genome. American Journal of Human Genetics, 2010, 87, 129-138.	2.6	111
6	The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies. BMC Genomics, 2015, 16, 403.	1.2	86
7	Multiple oncogenic mutations and clonal relationship in spatially distinct benign human epidermal tumors. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 20780-20785.	3.3	84
8	Common genetic variants in the PSCA gene influence gene expression and bladder cancer risk. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 4974-4979.	3.3	79
9	ISG15 and ISGylation is required for pancreatic cancer stem cell mitophagy and metabolic plasticity. Nature Communications, 2020, 11, 2682.	5.8	63
10	Differential distribution and enrichment of non-coding RNAs in exosomes from normal and Cancer-associated fibroblasts in colorectal cancer. Molecular Cancer, 2018, 17, 114.	7.9	61
11	Timeline of Development of Pancreatic Cancer and Implications for Successful Early Detection in High-Risk Individuals. Gastroenterology, 2022, 162, 772-785.e4.	0.6	60
12	Tumor-associated macrophage-secreted 14-3-3Î¶ signals via AXL to promote pancreatic cancer chemoresistance. Oncogene, 2019, 38, 5469-5485.	2.6	57
13	Palladin Mutation Causes Familial Pancreatic Cancer: Absence in European Families. PLoS Medicine, 2007, 4, e164.	3.9	54
14	Evaluation of the 4q32-34 Locus in European Familial Pancreatic Cancer. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 1948-1955.	1.1	50
15	Biomarkers for early diagnosis of pancreatic cancer. Expert Review of Gastroenterology and Hepatology, 2015, 9, 305-315.	1.4	36
16	A comprehensive analysis of candidate genes in familial pancreatic cancer families reveals a high frequency of potentially pathogenic germline variants. EBioMedicine, 2020, 53, 102675.	2.7	29
17	Increased plasma levels of galectin-1 in pancreatic cancer: potential use as biomarker. Oncotarget, 2018, 9, 32984-32996.	0.8	27
18	Soluble AXL is a novel blood marker for early detection of pancreatic ductal adenocarcinoma and differential diagnosis from chronic pancreatitis. EBioMedicine, 2022, 75, 103797.	2.7	20

#	Article	IF	Citations
19	Epigenetic Landscape in Pancreatic Ductal Adenocarcinoma: On the Way to Overcoming Drug Resistance?. International Journal of Molecular Sciences, 2020, 21, 4091.	1.8	17
20	sVEGFR2 and circulating tumor cells to predict for the efficacy of pazopanib in neuroendocrine tumors (NETs): PAZONET subgroup analysis.. Journal of Clinical Oncology, 2013, 31, 4140-4140.	0.8	17
21	Detection of Early-Stage Pancreatic Ductal Adenocarcinoma From Blood Samples: Results of a Multiplex Biomarker Signature Validation Study. Clinical and Translational Gastroenterology, 2022, 13, e00468.	1.3	17
22	A Label Free Disposable Device for Rapid Isolation of Rare Tumor Cells from Blood by Ultrasounds. Micromachines, 2018, 9, 129.	1.4	16
23	Macrophages direct cancer cells through a LOXL2-mediated metastatic cascade in pancreatic ductal adenocarcinoma. Gut, 2023, 72, 345-359.	6.1	15
24	Development of Temporal Temperature Gradient Electrophoresis for Characterising Methanogen Diversity. Microbial Ecology, 2005, 50, 327-336.	1.4	10
25	DNA Methylation Mediates EMT Gene Expression in Human Pancreatic Ductal Adenocarcinoma Cell Lines. International Journal of Molecular Sciences, 2022, 23, 2117.	1.8	8
26	Single-Nucleotide Polymorphism (SNP) Analysis to Associate Cancer Risk. Methods in Molecular Biology, 2009, 576, 171-196.	0.4	7
27	New targeted approaches against the ubiquitinâ€“proteasome system in gastrointestinal malignancies. Expert Review of Anticancer Therapy, 2012, 12, 457-467.	1.1	7
28	Primary Sarcomatoid Tumor of the Bladder: A Different Entity but the Same Approach?. Clinical Genitourinary Cancer, 2015, 13, 493-498.	0.9	7
29	Reply to â€˜Mosaic loss of chromosome Y in leukocytes mattersâ€™. Nature Genetics, 2019, 51, 7-9.	9.4	7
30	Biomarkers Associated with Regorafenib First-Line Treatment Benefits in Metastatic Colorectal Cancer Patients: REFRAME Molecular Study. Cancers, 2021, 13, 1710.	1.7	7
31	Ultrasounds in cancer therapy: A summary of their use and unexplored potential. Oncology Reviews, 2022, 16, 531.	0.8	5
32	Incidental findings in pancreas screening programs for highâ€risk individuals: Results from three European expert centers. United European Gastroenterology Journal, 2019, 7, 682-688.	1.6	3
33	Somatic Mutation Profiling in the Liquid Biopsy and Clinical Analysis of Hereditary and Familial Pancreatic Cancer Cases Reveals KRAS Negativity and a Longer Overall Survival. Cancers, 2021, 13, 1612.	1.7	3
34	Prognostic value of circulating endothelial cells in glioblastoma patients: a pilot study. Future Science OA, 2022, 8, .	0.9	2
35	Towards a more sensitive detection of somatic mutations in cell-free DNA. EBioMedicine, 2019, 41, 23.	2.7	1
36	Circulating endothelial cells: Prognostic value in patients with glioblastoma.. Journal of Clinical Oncology, 2019, 37, e13517-e13517.	0.8	1

#	Article	IF	Citations
37	Ultrasound Technology as a Novel Treatment Strategy in Pancreatic Cancer. Novel Approaches in Cancer Study, 2019, 2, .	0.2	1
38	Giant Macrophages: Characteristics and Clinical Relevance. , 2021, , 169-184.		0
39	Spanish national hereditary pancreatic cancer registry (PanFAM).. Journal of Clinical Oncology, 2012, 30, e12033-e12033.	0.8	0
40	Imaging techniques in pancreatic cancer screening: Preliminary results from the PanGen-FAM registry.. Journal of Clinical Oncology, 2013, 31, 1529-1529.	0.8	0
41	Survival surrogates in gastric cancer after first- and second-line chemotherapy treatment: A Spanish retrospective study from one institution.. Journal of Clinical Oncology, 2014, 32, e15019-e15019.	0.8	0
42	Prognostic factors in advanced gastric cancer after second-line treatment.. Journal of Clinical Oncology, 2015, 33, 201-201.	0.8	0
43	Genetic and phenotypic characterization of families with familial pancreatic cancer and screening of high-risk individuals.. Journal of Clinical Oncology, 2015, 33, 242-242.	0.8	0
44	KRAS mutant circulating free DNA (cfDNA) and circulating tumor cell (CTC) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer.. Journal of Clinical Oncology, 2015, 33, e15252-e15252.	0.8	0
45	Rectal adenocarcinoma: Results of adjuvant chemotherapy in a retrospective cohort.. Journal of Clinical Oncology, 2015, 33, e14539-e14539.	0.8	0
46	Circulating biomarkers exploratory study in loco-regional gastroesophageal adenocarcinoma patients.. Journal of Clinical Oncology, 2016, 34, 17-17.	0.8	0
47	Compliance and impact of screening on individuals at high risk of breast and ovarian cancer syndrome (BOCS).. Journal of Clinical Oncology, 2016, 34, e13054-e13054.	0.8	0
48	The PRECEDE consortium: A longitudinal international cohort study of individuals with genetic risk or familial pancreatic cancer.. Journal of Clinical Oncology, 2022, 40, e16239-e16239.	0.8	0